期刊文献+

多发性硬化的发病机制 被引量:9

The Pathogenesis of Multiple Sclerosis
原文传递
导出
摘要 多发性硬化是一种慢性的中枢神经系统炎性疾病,表现为中枢神经系统神经元的脱髓鞘。病程进展中出现少突神经胶质细胞损害和轴索破坏。尽管多发性硬化病因不清,目前已知自身免疫和感染是发病的重要因素,也有遗传因素参与其中。本文强调了B细胞的影响和膜脂肪代谢也是多发性硬化发病机制的重要因素,尤其与患者血浆、红细胞和白细胞、脑脊液中亚麻酸(C18:2n-6)和花生四烯酸(C20:2n-6)水平减少相关。 Multiple sclerosis is a chronic inflammatory disease of the central nerve system which leads to neuronal demyelination. In the aggressive disease course, oligodendrocytes and axons are destroyed and result in sclerotic plaques, or lesion formation. Although the underlying cause of multiple sclerosis remains unknown, both autoimmune and infectious are important factors which might initiate the inflammatory process. Metabolic disturbances, especially lipid metabolic abnormalities, have also been implicated in the pathogenesis of the disease and the decrease of C 18:2n-6(linoleic acid) and C20:4n-6(arachidonic acid) in blood plasma, platelets, white and red blood cells.
出处 《中国临床神经科学》 2013年第2期188-190,共3页 Chinese Journal of Clinical Neurosciences
关键词 多发性硬化 发病机制 脂肪酸代谢 B细胞 multiple sclerosis pathogenesis fatty acid metabolism B cell
  • 相关文献

参考文献11

  • 1郭丽萍.多发性硬化的治疗进展[J].中国临床神经科学,2012,20(4):440-444. 被引量:2
  • 2Scholz E, MiJller C. Multiple sclerosis: causes, Dignosis and Management[M]. Nova science New York,2012:1-57.
  • 3Mameli G, Astone V, Arru G, et al. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6[J]. J Gen Virol,2007,88:264-274.
  • 4Calder PC. Immunomodulation by omega-3 fatty acids[J]. Pros- taglandins Leukot Essent Fatty Acids,2007,77:327-335.
  • 5Calder PC. Polyunsaturated fatty acids, inflammation, and immunity [J]. Lipids,2001,36:1007-1024.
  • 6Adibhatla RM, Hatcher JF. Role of Lipids in Brain Injury and Diseases[J]. Future Lipidol,2007,2:403-422.
  • 7Adibhatla RM, Hatcher JF.Role of Lipids in Brain Injury and Diseases[J]. Future Lipidol,2007,2:403-422.
  • 8Chia LS, Thompson JE, Moscarello MA. Alteration of Lipid-phase be havior in multiple sclerosis myelin reveale by wide-angle X-ray diffraction[M]. Proc Natl Acad Sci USA,1984:1871-1874.
  • 9Craelius W, Gurmankin RS, Rosenheck DM, et al. Free fatty acid patterns in normal and multiple sclerosis white matter[J]. Acta Neurol Scand,1981,63:197-203.
  • 10Wilson R, Tocher DR. Lipid and fatty acid composition is altered in plaque tissue from multiple sclerosis brain compared with nor- mal brain white matter[J]. Lipids,1991,26:9-15.

二级参考文献10

  • 1Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis[J]. Ann Neurol,2006,60:12-21.
  • 2Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and sup- press macrophage infiltration[J]. Clin Exp Immunol,2006,145: 101-107.
  • 3Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, et al. Interleukin-8 and RANTES levels in patients with relapsing-re- mitting multiple sclerosis (RR-MS) treated with cladribine[J]. Acta Neurol Scand,2004,109:390-392.
  • 4Comi G. Oral laquinimod reduced relapse rate and delayed progression of disability in allegro, a placebo-controlled phase III trial for re- lapsing-remitting multiple sclerosis[J]. Neurology,2011,76:7PP.001.
  • 5O' Connor P, Wolinsky J, Confavreux C, et al. A placebo-controlled phase Ⅲ trial (TEMSO) of oral teriflunomide in relapsing mul- tiple sclerosis: clinical efficacy and safety outcomes[J]. Mult Scler, 2010,16:S23.
  • 6Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab(Campath-lH) treatment of multiple sclerosis[J]. J Clin Immunol,2010,30:99-105.
  • 7Kappos L, Calabresi P, O'Connor P, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: results of a phase II randomized placebo-controlled multicentre trial [J]. Mult Scler,2010,16:S33-S34.
  • 8Soelberg-Sorensen P, Drulovic J, Havrdova E, et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing- remitting multiple sclerosis (RRMS)-24-week results of a phase II study[J]. Mult Scler,2010,16:S37-38.
  • 9Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised,double-blind, placebo-controlled, add-on trial with interferon beta [J]. Lancet Neurol,2010,9:381-390.
  • 10王岚,丁正同.多发性硬化的治疗进展[J].中国临床神经科学,2010,18(3):299-306. 被引量:8

共引文献1

同被引文献81

  • 1陈健,房志仲.黄芪注射液的药理作用及临床应用[J].天津医科大学学报,2005,11(1):153-157. 被引量:42
  • 2陈可冀.血瘀证与活血化瘀治疗的研究[J].中国中医药现代远程教育,2005,3(11):10-12. 被引量:122
  • 3李晶华,王宗仁,邵中军,行利,马静,赵燕玲,龙铟,张德安.蜂毒肽抗风湿作用及对大鼠脊髓后角Fos表达的影响[J].神经解剖学杂志,2007,23(2):195-198. 被引量:2
  • 4Hood JL,Jallouk AP,Campbell N,et al.Cytolytic nanoparticles attenuate HIV-1infectivity[J].Antiviral Ther,2013,18(1):95-103.
  • 5Hauser RA,Daguio M,Wester D,et al.Bee-venom therapy for treating multiple sclerosis:a clinical trail[J].Altern Complem Ther,2001,7(1):37-45.
  • 6Karimi A,Ahmadi F,Parivar K,et al.Effect of honey bee venom on Lewis Rats with experimental allergic encephalomyelitis,a model for multiple sclerosis[J].Iranian J Pharmaceutical Res,2012,11(2):671-678.
  • 7Namaka M,Crook A,Doope A,et al.Examining the evidence:complementary adjunctive therapies for multiple sclerosis[J].Neuro Res,2008,30(7):710-719.
  • 8Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) [J]. Neurology, 1983, 33(11): 444-1452.
  • 9Scholz E, Mulle C. Multiple sclerosis [M]. New York:Nova Science Publisher Inc,2012:39-47.
  • 10Holman RT, Johnson SB, Kokmen E. Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis[J]. Proc Natl Acad Sci U S A, 1989,86:4720-4724.

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部